Rinehart K L,Holt T G,Fregeau N L,Ecteinascidins 729,743,745,759A,759B,and 770:potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate,Journal of Organic Chemistry,1990.
[2]
Scott J D,Williams R M,Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics,Chemical Reviews,2002(5).
[3]
Sessa C,De Braud F,Perotti A,Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails,Journal of Clinical Oncology,2005(9).
[4]
Zelek L,Yovine A,Brain E,A phase II study of Yondelis (trabectedin,ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer,British Journal of Cancer,2006(11).
[5]
Schoffski P,Wolter P,Clement P,Trabectedin (ET-743):evaluation of its use in advanced soft-tissue sarcoma,FUTURE ONCOLOGY,2007(4).
[6]
Grosso F,Jones R L,Demetri G D,Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas:a retrospective study,Lancet Oncology,2007(7).
[7]
Roylance R,Seddon B,McTiernan A,Experience of the use of trabectedin (ET-743,yondelistrade mark) in 21 patients with pretreated advanced sarcoma from a single centre,Clinical Oncology(royal College of Radiologists),2007(8).
[8]
Jordan M A,Kamath K,Manna T,The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth,Molecular Cancer Therapeutics,2005(7).
[9]
Krug L M,Miller V A,Kalemkerian G P,Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer,Annals of Oncology,2000(2).
[10]
Hoffman M A,Blessing J A,Lentz S S,A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma:a gynecologic oncology group study,Gynecologic Oncology,2003(1).
[11]
Perez E A,Hillman D W,Fishkin P A,Phase II trial of dolastatin-10 in patients with advanced breast cancer,Investigational New Drugs,2005(3).
[12]
Natsume T,Watanabe J,Koh Y,Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo,Cancer Science,2003(9).
[13]
de Jonge M J,van der Gaast A,Planting A S,Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027,given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors,Clinical Cancer Research,2005(10).
[14]
Greystoke A,Blagden S,Thomas A L,A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours,Annals of Oncology,2006(8).
[15]
Patel S,Keohan M L,Saif M W,Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy,Cancer,2006(12).
[16]
Riely G J,Gadgeel S,Rothman I,A phase 2 study of TZT-1027,administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy,Lung Cancer,2007(2).
[17]
Kerbrat P,Dieras V,Pavlidis N,Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer,European Journal of Cancer,2003(3).
[18]
Marks R S,Graham D L,Sloan J A,A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer,American Journal of Clinical Oncology,2003(4).
[19]
Smyth J,Boneterre M E,Schellens J,Activity of the dolastatin analogue,LU103793,in malignant melanoma,Annals of Oncology,2001.
[20]
McDermott D F,Hersh E,Weber J,ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma:Phase II experience,Journal of Clinical Oncology,2005.
[21]
Moneo V,Serelde B G,Leal J F,Levels of p27(kip1) determine Aplidin sensitivity,Molecular Cancer Therapeutics,2007(4).
[22]
Vera M D,Joullie M M,Natural products as probes of cell biology:20 years of didemnin research,Medicinal Research Reviews,2002(2).
[23]
Cuadrado A,Garcia-Fernandez L F,Gonzalez L,Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor,Src,JNK,and p38 MAPK,Journal of Biological Chemistry,2003(1).
[24]
Gonzalez R,Ebbinghaus S,Henthorn T K,Treatment of patients with metastatic melanoma with bryostatin-1-a phase II study,Melanoma Research,1999(6).
[25]
Zonder J A,Shields A F,Zalupski M,A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer,Clinical Cancer Research,2001(1).
[26]
Blackhall F H,Ranson M,Radford J A,A phase II trial of bryostatin 1 in patients with non-Hodgkin\'s lymphoma,British Journal of Cancer,2001(4).
[27]
Varterasian M L,Pemberton P A,Hulburd K,Phase II study of bryostatin 1 in patients with relapsed multiple myeloma,Investigational New Drugs,2001(3).
[28]
Clamp A R,Blackhall F H,Vasey P,A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma,British Journal of Cancer,2003(7).
[29]
Haas N B,Smith M,Lewis N,Weekly bryostatin-1 in metastatic renal cell carcinoma:a phase II study,Clinical Cancer Research,2003(1).
[30]
Nezhat F,Wadler S,Muggia F,Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix:a New York gynecologic oncology group study,Gynecologic Oncology,2004(1).
[31]
Peterson A C,Harlin H,Karrison T,A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma,Investigational New Drugs,2006(2).
[32]
Ajani J A,Jiang Y,Faust J,A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated,advanced gastric or gastroesophageal junction adenocarcinoma,Investigational New Drugs,2006(4).
[33]
Rademaker-Lakhai J M,Horenblas S,Meinhardt W,Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer,Clinical Cancer Research,2005(5).
[34]
Suarez Y,Gonzalez L,Cuadrado A,Kahalalide F,a new marine-derived compound,induces oncosis in human prostate and breast cancer cells,Molecular Cancer Therapeutics,2003(9).
[35]
Janmaat M L,Rodriguez J A,Jimeno J,Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling,Molecular Pharmacology,2005(2).
[36]
Pietras R J,Weinberg O K,Antiangiogenic Steroids in Human Cancer Therapy,Evidence-based Complementary and Alternative Medicine,2005(1).
[37]
Hao D,Hammond L A,Eckhardt S G,A Phase I and pharmacokinetic study of squalamine,an aminosterol angiogenesis inhibitor,Clinical Cancer Research,2003(7).
[38]
Herbst R S,Hammond L A,Carbone D P,A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer,Clinical Cancer Research,2003(11).
[39]
Anderson H J,Coleman J E,Andersen R J,Cytotoxic peptides hemiasterlin,hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation,Cancer Chemotherapy and Pharmacology,1997(3).
[40]
Krishnamurthy G,Cheng W,Lo M C,Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules,Biochemistry,2003(46).
[41]
Ratain M J,Undevia S,Janisch L,Phase 1 and pharmacological study of HTI-286,a novel antimicrotubule agent:Correlation of neutropenia with time above a threshold serum concentration,Proceedings of the American Society of Clinical Oncology,2003.
[42]
Loganzo F,Hari M,Annable T,Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin,Molecular Cancer Therapeutics,2004(10).
[43]
De Souza M V,(+)-discodermolide:a marine natural product against cancer,Scientific World Journal,2004.
[44]
Klein L E,Freeze B S,Smith A B 3rd,The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence,Cell Cycle,2005(3).
[45]
Mita A,Lockhart A C,Chen T L,A phase I pharmacokinetic(PK)trial of XAA296A(Discodermolide)administered every 3 wks to adult patients with advanced solid malignancies,Journal of Clinical Oncology,2004(14S).
[46]
Simmons T L,Andrianasolo E,McPhail K,Marine natural products as anticancer drugs,Molecular Cancer Therapeutics,2005(2).
[47]
Rowinsky E K,de Bono J,Deangelo D J,Cardiac monitoring in phase I trials of a novel histone deacetylase(HDAC)inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies,Journal of Clinical Oncology,2005(16S).
[48]
Kinder F R J,Versace R W,Bair K W,Synthesis and antitumor activity of ester-modified analogues of bengamide B,Journal of Medicinal Chemistry,2001(22).
[49]
Dumez H,Gall H,Capdeville R,A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer,Anti-Cancer Drug Design,2007(2).
[50]
Natori T,Morita M,Akimoto K,Agelasphins,novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus,Tetrahedron Letters,1993.
[51]
Shimosaka A,Role of NKT cells and alpha-galactosyl ceramide,International Journal of Hematology,2002(z1).
[52]
Giaccone G,Punt C J,Ando Y,A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors,Clinical Cancer Research,2002(12).
[53]
Ishikawa A,Motohashi S,Ishikawa E,A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer,Clinical Cancer Research,2005(5).
[54]
Motohashi S,Ishikawa A,Ishikawa E,A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer,Clinical Cancer Research,2006(20 Pt 1).
[55]
Cuadros R,Montejo de Garcini E,Wandosell F,The marine compound spisulosine,an inhibitor of cell proliferation,promotes the disassembly of actin stress fibers,Cancer Letters,2000(1).
[56]
Faircloth G,Cuevas C,Kahalalide F and ES285:potent anticancer agents from marine mollusks,Progress in Molecular and Subcellular Biology,2006.
[57]
Tsukamoto S,Yamashita K,Tane K,Girolline,an antitumor compound isolated from a sponge,induces G2/M cell cycle arrest and accumulation of polyubiquitinated p53,Biological and Pharmaceutical Bulletin,2004(5).
